CURRICULUM VITAE

Part I: General Information

Date Prepared: April 3, 2008

Name: Howard Alan Fine

Office Address: Neuro-Oncology Branch

> National Cancer Institute
>
> National Institutes of Health
>
> Bloch Building #82
>
> 9030 Old Georgetown Road
>
> Room 235, MSC 8200
>
> Bethesda, MD 20892-8200

Home Address: 10328 Windsor View, Potomac MD 20854

E-Mail: hfine@mail.nih.gov; Telephone: (301) 402-6383; FAX: (301)
480-2246

Place of Birth: Newport News, Virginia

Education:

1980 B.A. University of Pennsylvania, Philadelphia, PA (summa cum laude)

1984 M.D. Mount Sinai School of Medicine, New York, NY

Postdoctoral Training:

June 1984 -- June 1985 Intern in Medicine, Hospital of The University of
Pennsylvania, Philadelphia, PA

June 1985 -- June 1987 Resident, Internal Medicine, Hospital of The
University of Pennsylvania

June 1987 -- June 1990 Fellow in Medical Oncology, Dana-Farber Cancer
Institute, Brigham and Women\'s Hospital, Harvard Medical School Boston,
MA

Licensure and Certification:

1987 Massachusetts Medical Licensure (#72983)

1987 Board Certified in Internal Medicine (#115068)

1990. Board Certified in Medical Oncology (#115068)

2000 Maryland Medical Licensure (#D0055925)

Academic Appointments:

June 1991 -- June 1994 Instructor in Medicine, Harvard Medical School

June 1994 -- March 2000 Assistant Professor of Medicine, Harvard Medical
School

March 2000- Present Senior Investigator, National Cancer Institute, NIH

Hospital or Affiliated Institution Appointments:

June 1991 -- March 2000 Associate Physician, Brigham and Women\'s
Hospital

June 1991 -- June 1994 Instructor in Medicine, Division of Cancer
Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School

June 1994 -- March 2000 Assistant Professor of Medicine, Division of
Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical
School

June 1995 -- March 2000 Assistant Physician, Beth Israel Hospital

June 1996 -- March 2000 Assistant Physician, Massachusetts General
Hospital

March 2000 -- Present Senior Investigator, Physician, The Clinical
Center, NIH

November 2004 -- Present Adjunct Professor, Neurology and Pediatrics,
The George Washington University School of Medicine and Health Sciences

February 2007-Present Adjunct Professor, North Carolina State University

February 2008 -- Present Associate Membership in the Graduate Faculty,
North Carolina State University

Hospital and Health Care Organization Service Responsibilities:

Jan 1998 -- March 2000 Disease Center Leader, Neuro-Oncology,
Dana-Farber Cancer Institute

March 2000 - Present Chief, Neuro-Oncology Branch, National Cancer
Institute (NCI), National Institute of Neurological Disorders and Stroke
(NINDS), National Institute of Health (NIH)

Major Administrative Responsibilities:

1997 - 2000 Scientific Review Committee, Dana-Farber Cancer Institute,
Brigham and Women's Hospital, MGH, Joint Venture IRB

1998 - 2000 Neuro-Oncology Program, Dana-Farber Cancer Institute

1998 - 2000 Dana-Farber Cancer Institute/Harvard Cancer Center
Neuro-Oncology Program Leader-Medical School, Dana Farber Cancer
Institute, Brigham and Women's Hospital, The Children's Hospital, MGH,
Beth Israel Deaconess

2000 - Chief, Neuro-Oncology Branch, National Cancer Institute (NCI),
National Institute of Neurologic Disease and Stroke (NINDS), National
Institute of Health (NIH)

Major Committee Assignments:

1996 - Brain Tumor Committee, Radiation Therapy Oncology Group (RTOG)

1996 - 2000 Scientific Review Board/IRB, Dana-Farber/Partner\'s Cancer
Center

1997 - 2000 Co-Chair, Clinical Investigator Committee, Dana-Farber
Cancer Institute

1997 - National Comprehensive Cancer Network: Neuro-Oncology Committee

1997 - Medical Advisory Board, Brain Tumor Society

1997 - 2000 Program Leader, Program in Neuro-Oncology, Dana-Farber
Cancer Institute, Harvard Cancer Center

1998 - Brain Disorders and Clinical Neuro-Science-4 (BDCN-4) Study
Section, National Institute of Neurologic Disease and Stroke (NINDS),
NIH

1999 - American Joint Committee on Cancer (AJCC), American College of
Surgeons Brain Tumor Committee

2000. Protocol Review and monitoring Committee, National Cancer
      Institute, NIH

> NCI/NINDS CNS Tumor Progress Review Group (PRG) organizing and
> oversight committee; Chairperson CNS Tumor "Treatment" subcommittee

2000. Physician Data Query (PDQ) Editorial Board for CNS Tumor, gene
      therapy and anti-angiogenesis clinical trials

2000- Brain Tumor Program Review Group (PRG) Steering Committee, NCI,
NINDS, NIH

2002- Board of Directors, Society of Neuro-Oncology

2003- Committee Member and Tutor, NIH Clinical Research Training Program
(CRTP)

2003- Co-Chair, Clinical Trials Working Group, NCI, NIH

2003- Clinical Executive Committee, Center for Cancer Research, NCI, NIH

2005 Committee Member and Tutor, NIH Howard Hughes Institute (HHMI)
Medical Scholars Program

2006: Co-Chair: FDA-AACR-Sponsored Brain Tumor Endpoints Workshop,
Bethesda, MD

Professional Societies:

1988 - American Association for the Advancement of Science

1994 - American Society of Clinical Oncology

1999 - Society for Neuro-Oncology

Community Service Related to Profession Work:

1995 - Annual invited speaker and panel discussant, \"Pathways to
Progress\", Brain Tumor Society\'s national, annual patient and family
meeting

1997 - Medical Advisory Board, Brain Tumor Society

Editorial Boards:

1989 ad hoc reviewer: Journal of Acquired Immunodeficiency Syndrome

1990 ad hoc reviewer: Journal of Clinical Oncology

1992 ad hoc reviewer: Cancer

1994 ad hoc reviewer: Cancer Research

1994 ad hoc reviewer: New Engl. J Med.

1994 ad hoc reviewer: J Neuro-Oncology

1994 ad hoc reviewer: New Engl. J Med

1995 ad hoc reviewer: Nature Medicine

1996 ad hoc reviewer: Gene Therapy

1996 ad hoc reviewer: J Clin Investigation

1996 ad hoc reviewer: Annals of Neurology

1997. Editorial Board: Journal of Clinical Oncology

1998. ad hoc reviewer: J Clinical Cancer Research

2000 Editorial Board: Neuro-Oncology

2000 Associate Editor: The Oncologist

2002 Editorial Board: Clinical Proteomics

2007 Editorial Board: Neuro-Oncology

Awards and Honors:

1976 National Honor Society

1980 Phi Beta Kappa, University of Pennsylvania

1980 Diploma of \"Special Honors and Distinction in the Biological
Sciences\", University of Pennsylvania

1980 Summa Cum Laude

1983 Junior Alpha Omega Alpha, Medical Honor Society, Mount Sinai School
of

Medicine

1984 \"Harold Elster Memorial Prize\", for student graduating at the top
of the class,

> Mount Sinai School of Medicine

1990 American Cancer Society Physician Scientist Career Development
Award

1991 NIH Physician Scientist Award

1992 Brain Tumor Society Research Award

1993 Emil Frei III Dana-Farber Cancer Institute Clinical Investigator
Award

1999 Dana-Farber Harvard Cancer Center, Clinical Investigator Award

2004 NCI Director's Gold Star Award 2004, for vision, leadership and
advice in designing cancer programs for the future using neuro-oncology
as a model

2005 The National Service to America Award (awarded to the REMBRANDT
team)

PART II: Teaching and Clinical Contributions

A. Funding Information

1990-1991 American Cancer Society Physician Research Training Grant

1991-1996 Physician Scientist Award 5 K11 CA01467-03 PI Role of HTLV-1
X-Region in Cellular Transformation

1992-1994: Brain Tumor Society Laboratory Development Grant.
\"Investigation of Potential Novel Therapeutic Molecular Targets in
Gliomas\" (Principal Investigator).

1993-1996: Emil Frei III Clinical Investigator Award.

1994-1998: RFA: CA-93-07: \"Phase I Trials of New Anti-cancer Agents\"
(Co-investigator with Donald W. Kufe, M.D.)

1994-1998: RFA: CA-93-03: \"Therapeutic Studies of Primary CNS
Malignancies in Adults\": (Principal Investigator)

1994-1999: DAMD17-94-J-4394: Gene Therapy of Breast Cancer: Studies of
selective promoter/enhancer modified vectors to deliver suicide genes
(Co-Principal Investigator with Donald W. Kufe, M.D.)

1998-2002: RFA: CA-97-05: "Therapeutic Studies of Primary CNS
Malignancies in Adults:" (Principal Investigator)

1998-2001 DAMD 98-"Viral Vector Targeted Antiangiogenic Gene Therapy"
(Principal Investigator)

1999-2002 J.S. McDonnell Foundation: Endothelial-Based vectors for the
treatment of Malignant gliomas

B. Report of Current Research

> *[Clinical Research:]{.underline} (a sampling of IRB-approved trials
> that H. Fine initiated and was/is principal investigator)*
>
> • Phase II aIFN/5-FU/BCNU for Recurrent Glioma
>
> • Phase I Trial of BG9015 (r-IFN beta) in Recurrent Gliomas
>
> • Pre-XRT COP Chemotherapy for Newly Diagnosed Gliomas
>
> • Pharmacokinetic Study of I.V. Thiotepa for Carcinomatous Meningitis

• Upfront Chemotherapy with aIFN/5-FU/BCNU for Newly Diagnosed High
Grade Gliomas

• Phase I Evaluation of r-IFN Beta in Patients with Recurrent
Astrocytomas

• Phase I Trial of TNP-470 (AGM-1470), a New Inhibitor of Angiogenesis

• Phase I Trial of Intratumoral Administered Recombinant Platelet Factor
4 in Refractory/Recurrent Glioblastoma

> • Phase I/II Trial of Thalidomide for Recurrent High Grade Astrocytoma
>
> • Phase II Trial of BBBD with RMP7 /Carboplatin
>
> • Phase II Trial of High Dose Lovastatin in Recurrent Gliomas

• Phase II Trial of TNP-470 in Patients with Newly Diagnosed
Glioblastoma Multiforme Following Standard External Beam Radiation.

• Phase III Randomized Trial of Intensive PCV Chemotherapy Versus
Standard Radiotherapy in Patients with Newly Diagnosed Malignant
Oligodendrogliomas.

> • A Phase I/II Trial of CI-980 for Recurrent High Grade Gliomas.
>
> • A Phase II Trial of Bryostatin for Recurrent Gliomas.
>
> • A Phase II Trial of Beta Interferon for Recurrent Gliomas.

• A Phase I/II Evaluation of BCNU and Temozolomide for Newly diagnosed
Anaplastic Gliomas and recurrent Glioblastoma.

• A Phase II Trial of Thalidomide and BCNU for Recurrent High Grade
Gliomas.

• A Phase II Trial Beta Interferon, High Dose Tamoxifen, and Minocycline
for Newly Diagnosed Glioblastoma

• A Case-Control Trial of the Risk of Environmental and Occupational
Exposure for the Development of primary brain Tumors

• A Phase II Trial Beta Interferon, High Dose Tamoxifen, and Minocycline
for Recurrent High Grade Gliomas

• A Phase I Trial of PKT-787, and Inhibitor of FLK-1, for Patients with
Advanced Cancer

• A Phase II Trial of Thalidomide and External Beam Radiotherapy for
patients with newly diagnosed Glioblastoma

• A Phase I Trial of TNP-470 and BCNU for Patients with Glioblastoma
Following Standard Fractionated Radiotherapy

• A Phase I/II Trial of SU5416, a FLK and Angiogenesis Inhibitor, in
Patients with Recurrent malignant Gliomas

• A Phase I Trial of CC-5013, a potent thalidomide analog, in patients
with recurrent primary brain tumors

• A Phase II Trial of LY317615, a PKC beta inhibitor, in patients with
recurrent high grade gliomas

• A Phase II trial of Talampanel, a new AMPA glutamate receptor
inhibitor, for patients with recurrent high-grade gliomas

• A Phase I trial of CC-8490, a new selective estrogen receptor
modulator with potent anti-glioma activity

• A Prospective National Study to Molecularly and Genetically
Characterize Human Gliomas: The Glioma Molecular Diagnostic Initiative
(GMDI)

• A Phase II trial of Tamoxifen and Bortezomib in patients with
recurrent high-grade gliomas

• A Phase I trial of Enzastaurin (LY317615) in patients with recurrent
glioma

• A Randomized Phase II study of Peg-Interferon Alpha-2B (Peg-Intron™)
and Thalidomide in adults with recurrent high grade gliomas

• Evaluation of the natural history of patients with tumors of the
central nervous system

> • A Phase I/II Study of ATN‑161 and carboplatin in adult patients with
> recurrent intracranial malignant glioma
>
> • A Phase I/II Trial of ZD6474 for Patients with Recurrent High Grade
> Gliomas
>
> • A Phase I/II Trial of Talampanel in Conjunction With Radiation
> Therapy with Concurrent and Adjuvant Temozolomide in Patients with
> Newly Diagnosed Glioblastoma Multiforme
>
> • A Pilot and feasibility phase I trial of ferrodex-labeled
> endothelial progenitor cells as MRI-imaged markers of in situ
> vasculogenesis/angiogenensis in malignant gliomas
>
> • A Imaging and biological correlate-guided phas II trial of
> Bevacizumab in patients with recurrent high-grade gliomas

• A Phase I trial of Enzastaurin in combination with carboplatin for
patients with recurrent gliomas

> • An International Randomized Phase III Study of Enzastaurin Versus
> Lomustine in the Treatment of Recurrent, Intracranial Glioblastoma
> Multiforme
>
> *[Laboratory Research]{.underline}:*

1)  The molecular and genetic characterization of human gliomas for the
    purpose of redefining a glioma taxonomy and for the identification
    and ultimate validation of new molecular targets and patient
    specific subgroups for therapeutic drug discovery.

2)  Exploration of the translational/therapeutic potential of stem cell
    biology in gliomas.

3)  The pre-clinical and clinical development of novel molecularly

> targeted agents for the treatment of gliomas.

C. Report of Teaching

> *1. Local Contributions*
>
> d\. Continuing medical education courses:
>
> 1\. 1991
>
> \"Chemotherapy of Primary and Metastatic Brain Tumors\" in Neurology
> Updates. A CME course sponsored by The Longwood Medical Area and
> Brigham and Women\'s Hospital Division of Neurology, and the Harvard
> Medical School Lecturer
>
> 2\. 1991, 1993, 1995, 1997, 1999, 2001
>
> \"Neuro-Oncology\" in Cancer Medicine. A CME course sponsored by the
> Dana-Farber Cancer Institute and Harvard Medical School Lecturer
>
> 3\. 1992-1996
>
> "Drug Therapy in the Treatment of Astrocytomas. In Tumors of the
> Central Nervous System". A CME course sponsored by the Brain Tumor
> Center, Brigham and Women's Hospital, The Dana-Farber Cancer
> Institute, and Harvard Medical School Lecturer
>
> 4\. 1993-1996
>
> \"Innovative Therapeutic Approaches to the Treatment of Primary and
> Metastatic Brain Tumors\" in Neurology Updates. A CME course sponsored
> by The Longwood Medical Area, and Brigham and Women\'s Hospital
> Division of Neurology, and the Harvard Medical School Lecturer
>
> 5\. 1997-1999
>
> "Novel Biologic Therapies, Including Gene Therapy and Angiogenesis, in
> the Treatment of Malignant Gliomas. In Tumors of the Central Nervous
> System". A CME course sponsored by the Brain Tumor Center, Brigham and
> Women's Hospital, The Dana-Farber Cancer Institute, and Harvard
> Medical School Lecturer
>
> f\. Teaching leadership role in department/affiliated Institution
> Medical School/School of Dental Medicine (organization of course,
> director of training programs, etc.)
>
> 1\. 1989-2000
>
> Assistant Professor of Medicine
>
> Teaching neuro-oncology to the Dana-Farber oncology fellows and the
> Brigham and Women's hematology fellows

2\. 2000-

> Senior Investigator, Branch Chief
>
> Teaching neuro-oncology to NCI adult medical pediatric, and radiation
> oncology fellows
>
> 3\. 2000-
>
> Co-Director of the NIH-Johns Hopkins Medical Center Neuro-Oncology
> Fellowship Program
>
> *2. Regional, national, or international contributions*
>
> a\. Invited presentations (e.g., visiting professorship, invited
> lecture, plenary
>
> presentation, seminar)
>
> 1\. 1993 Invited lecturer: "Identifying Vectors for Gene Therapy"
>
> Joint Section on Tumors Workshop, Congress of Neurological Surgeons
> Annual Meeting, Vancouver, B.C.
>
> 2\. 1995 Invited lecturer: \"Novel Gene Therapy Strategies for
> Malignant Gliomas"
>
> Recent Advances in Biotechnology, University of Montreal, Montreal
> Canada
>
> 3\. 1995 Invited lecturer: \" Novel Biologic-Based Therapies for
> Malignant Gliomas"
>
> American Society for Therapeutic Radiotherapy and Oncology (ASTRO),
> Miami Beach, FL
>
> 4\. 1996 Invited lecturer: \"Gene Therapy for Malignant gliomas\"
>
> American Academy of Neurology. San Francisco, CA
>
> 5\. 1998 Seminar: "Current Approaches to the Treatment of Malignant
> Gliomas Educational Symposium", American Society of Clinical Oncology
> (ASCO) Los Angeles, CA.
>
> 6\. 1998 Seminar: "Tumor -Selective Transgene Expression Mediated by
> E2F-Responsive Viral Vectors" Special Gene Therapy Seminar
>
> American Association of Cancer Research (AACR), New Orleans, LA
>
> 7\. 1998 Seminar: "Novel Therapeutic Strategies for Malignant Gliomas"
>
> American Society of Therapeutic and Radiation Oncology (ASTRO),
> Phoenix, AZ
>
> 8\. 1998 Seminar: \"Targeted Anti-angiogenesis Utilizing a Modified
> PF4 cDNA\", European Congress of Gene Therapy, Paris France
>
> 9\. 1999 Seminar: \"Tumors of the Central Nervous System\", American
>
> 2000 School of Oncology, Board Review Course, Atlanta, GE
>
> 10\. 1999 Seminar: \"Neuro-Oncology\", Hematology Oncology Board
> Review
>
> 2000 Course, The George Washington Medical center, Washington D.C.
>
> 11\. 1999 Seminar: \"Angiogenesis Inhibitors\", Pediatric
> Neuro-Oncology Symposium: State of the Art Therapy for Children With
> Brain Tumors, Minneapolis, MN
>
> 12\. 1999 Grand Rounds: \"Novel Biologic Therapies for Malignant
> Gliomas\", Ohio State Cancer Center, Columbus, OH
>
> 13\. 1999 Seminar: \"Anti-angiogenic and Gene Therapy Strategies for
> Malignant Gliomas\", Annual Meeting of The Society of Neuro-Oncology,
> Scottsdale, AZ.
>
> 14\. 2000 Seminar: \"Biology and New Therapeutic Strategies for
> Primary Central Nervous System Lymphoma\", Diagnosis and Treatment of
> Neoplastic Disorders, Johns Hopkins cancer Center, Baltimore, MD
>
> 15\. 2000 Discussant: Summary, Analyses, and Prospective of Central
> nervous System Tumor Abstract Presentations, American Society of
> Clinical Oncology (ASCO), New Orleans LA.
>
> 16\. 2000 Invited Speaker: "Neuro-Oncology" Network for Oncology
> Communications -- State of the Art II, Atlanta GA
>
> 17\. 2000 Grand Rounds: "Novel Targeting approaches to for Malignant
> Gliomas"; University of Michigan cancer Center, Ann Arbor, MI.
>
> 18\. 2000 Discussant: American Joint Committee on Cancer Central
> Nervous Task Force Meeting, Colorado Springs, CO.
>
> 19\. 2000 Seminar: "New advances in Neuro-Oncology" Cancer Medicine
> Course, Dana-Farber Harvard Cancer Center, Boston, MA
>
> 20\. 2000 Invited Speaker: "New brain tumor initiatives at the NIH",
> The Annual Meeting of the Society of Neuro-Oncology, South Carolina.
>
> 21\. 2000 Invited Speaker: Presidents Research Seminar: "New
> approaches to selective glioma targeting of genetic vectors in vivo",
> Memorial Sloan Kettering Cancer Center, NYC, NY.
>
> 22\. 2000 Grand Rounds: Novel Therapeutic Strategies for Malignant
> Gliomas. National Cancer Institute, Bethesda, MD.
>
> 23\. 2000 Grand Rounds: Glioma-Selective Gene Targeting. Lombardi
> Cancer Center, Georgetown Medical Center, Washington, DC.
>
> 24\. 2001 Invited Speaker: "Brain Cancer" The George Washington
> University Medical Center, Washington, DC
>
> 25\. 2001 Invited Speaker/Discussant: Brain Tumor Awareness Week 2001
> Congressional Luncheon -- Capitol Hill, Washington, DC
>
> 26\. 2001 Invited Speaker: "Chemotherapy: Standard and Novel
> Therapies" Update in Clinical Neurosciences Johns Hopkins University,
> Baltimore, MD
>
> 27\. 2001 Seminar: \"Clinical trials of Anti-angiogenic Agents in
> Malignant Gliomas\", The Every Three Year Meeting of The Society of
> Neuro-Oncology, and World Federation of Neuro-Oncology, Washington,
> DC.
>
> 28\. 2001 Keynote Address: New NCI/NINDS Initiatives in Brain Tumor
> Research, The Every Three Year Meeting of The Society of
> Neuro-Oncology, and World Federation of Neuro-Oncology, Washington, DC
>
> 29\. 2001 Seminar: Stem Cell Plasticity and Cell-Mediated Gene
> Transfer. Henry Ford Cancer Center, Detroit MI.
>
> 30\. 2002 Grand Rounds: Neuro-Science Program, Children's National
> Medical Center
>
> 31 2002 Grand Rounds: "Novel Therapeutic Approaches for Malignant
> Gliomas", Lombardi Cancer Center, Georgetown Medical Center,
> Washington, D.C.
>
> 32\. 2002 Speaker: "Bone Marrow to Brain Tumors: Changing Paradigms
> and Their Therapeutic Implications", Grand Rounds, Center for Cancer
> Research, National Cancer Institute, National Institute of Health,
> Bethesda, MD
>
> 33\. 2002 Speaker: "Presentation of the Results of Trial NABTC-9902,
> SU5416 for Recurrent High Grade Gliomas", Cancer Therapy and
> Evaluation Program (CTEP) Spring Phase I Meeting, Investigational Drug
> Branch (IDB) of the Division of Cancer Treatment and Diagnosis,
> National Cancer Institute of the National Institutes of Health,
> Bethesda
>
> 34\. 2002 Speaker: "The Neuro-Oncology Branch of the National Cancer
> Institute", Annual Meeting of the North American Brain Tumor Coalition
> (NABTC), Washington, D.C.
>
> 35\. 2002 Speaker: "From Bone Marrow to Brain Tumors: New Paradigms
> and Their Therapeutic Implications", Washington Cancer Institute,
> Washington Hospital Center, Washington, D.C.
>
> 36\. 2002 Speaker: "In Vitro Expansion, Gene Expression Profiling, and
> Therapeutic Application of Human Adult Bone-Marrow-Derived Neural
> Stem-like Cells", 10^th^ SPORE Investigators' Workshop, Chantilly, VA
>
> 37\. 2002 Speaker: "Neuro-Oncology", Hematology/Medical Oncology Board
> Review, The George Washington University Medical Center, Alexandria,
> VA
>
> 38\. 2002 Speaker: "Central Nervous System: New Therapeutic
> Approaches", 2002 Annual Meeting of the American Society of Clinical
> Oncology, Orlando, FL
>
> 39\. 2003 Speaker: Comprehensive Molecular Analysis of Human Gliomas
> and medulloblastomas, Neuro-Oncology Branch and the Cancer Diagnosis
> Program of the National Cancer Institute and the National Institute of
> Neurological Disorders and Stroke of the National Institutes of
> Health, Bethesda, MD
>
> 40\. 2003 Speaker: "Bone Marrow to Brain Tumors: Changing Paradigms
>
> and Their Therapeutic Implications", National Institutes of
>
> Health's Clinical Center Grand Rounds 50^th^ Anniversary Lecture,
>
> Bethesda, MD
>
> 41\. 2003 Speaker: "Neuro-Oncology", Hematology/Medical Oncology Board
> Review, The George Washington University Medical Center, Alexandria,
> VA
>
> 42\. 2004 Invited Speaker: "Anti-Angiogenic Therapy for Primary CNS
> Malignancies: Efficacy and Safety Analysis", The Sixth International
> Symposium on Anti-Angiogenic Agents, San Diego, CA
>
> 42\. 2004 Speaker: "Chemotherapeutics", Sharing Hope: Brain Tumor
> Meeting for Survivors and Families, the American Brain Tumor
> Association and the Childhood Brain Tumor Foundation, Washington, DC
>
> 43\. 2004 Speaker: "Bone Marrow to Brain Tumors: Changing Pradigms and
> Their Therapeutic Implications", Neurosurgery Grand Rounds, Washington
> Hospital Center, Washington, DC
>
> 44\. 2004 Speaker: "Neuro-Oncology", Hematology/Medical Oncology Board
> Review, The George Washington University Medical Center, Alexandria,
> VA
>
> 45\. 2005 Speaker: "Results of a Phase II Trial of LY317615 in
> Patients with Recurrent High-Grade Gliomas" (ASCO) Orlando, FL
>
> 46\. 2005 Keynote Speaker: Annual RTOG Meeting, Philadelphia, PA
>
> 47\. 2006 Invited Lecturer: " Malignant Gliomas and Neural Stem Cells
> Gone Bad: The Biological and Therapeutic Implications of a Changing
> Paradigm", Rena Schechter Memorial Lecture-Siteman Cancer Center,
> Washington University School of Medicine, St. Louis, MO
>
> 48\. 2006 Speaker: "Therapies in Clinical Trial: Today and Tomorrow",
> Accelerate Brain Cancer Cure Scientific Retreat, Accelerate Brain
> Cancer Cure (ABC2), Tucson, AZ
>
> 49\. 2006 Speaker: " Experience with Enzastaurin in GBM Clinical
> Trial: GSK3 Beta as a Biomarker", Lilly Biomarker Programs and their
> application to Cancer Drug Development, Miami, FL
>
> 50\. 2006 Speaker: "Treatments for patients with Gliomas: Current
> Standards and Promising New Approaches (tele/web conference)",
> National Brain Tumor Foundation (NBTF), San Francisco, CA
>
> 51\. 2006 Speaker: "Malignant Gliomas; a Neural Stem Cell Gone Bad.
> The Biological and Therapeutic Implications of a Changing Paradigm",
> 140^th^ regular meeting of the National Cancer Advisory Board (NCAB),
> National Institutes of Health, Bethesda, MD
>
> 52\. 2006 Speaker: "Analyzing Brain Cancer in a big way", Cancer
> Biomedical Informatics Grid (caBIG), National Cancer Institute,
> National Institutes of Health, Bethesda, MD
>
> b\. Professional and educational leadership roles related to teaching
> (e.g., program chair for professional society annual meeting or member
> of steering committee)
>
> 1\. 1993-1998: Co-sponsor and organizer (with Peter McL. Black, Chief
> of
>
> Neurosurgery, Brigham and Women's and Children's Hospital) of
>
> International Conference: \"Growth Control in Central Nervous System
>
> Tumors\"

2\. 1994: Program Committee, Central Nervous System Tumor
Representative,

American Society of Clinical Oncology (ASCO), Orlando FL

> 3\. 1996: Program Committee, Central Nervous System Tumor
> Representative,
>
> American Society of Clinical Oncology (ASCO), Philadelphia, PA
>
> 4\. 2000: Steering Committee, Brain Tumor Program Review Group, NCI,
>
> NINDS, NIH.

5.  2001: Program Chairperson; "CNS Tumors", American Association of

> Cancer Research (AACR), New Orleans, LA.
>
> 6\. 2002: Board of Directors, Society of Neuro-Oncology

7\. 2003: Steering Committee, Clinical Research Training Program, NIH

8\. 2005: Howard Hughes Medical Institute (HHMI) Scholars Program, NIH.

D. Report of Clinical Activities

> 1988-2000 Organized, administered and participation in patient care of
> the Brain Tumor Clinic at Dana-Farber Cancer Institute.
>
> 2000- Created the entire clinical and administrative infrastructure
> for caring for neuro-oncology patients in the multidisciplinary adult
> and pediatric brain tumor clinic at the NIH.

**BIBLIOGRAPHY:**

[Original Reports]{.underline}

> 1\. [Fine HA]{.underline}, Levine GM, Shiau Y-F. Effects of
> cholecystokinin-octopeptide and secretin on intestinal structure and
> function. Am J Phys. 245: G358-G363, 1983.
>
> 2\. Loeffler JS, Kooy H, Wen P, [Fine HA]{.underline}, Cheng C,
> Mannarino E, Tsai J, Alexander E. The treatment of recurrent brain
> metastasis with stereotactic radiosurgery. J Clin Oncol. 8(4): 576-82,
> 1990.
>
> 3\. Loeffler JS, Alexander E III, Wen PY, Shea WM, Coleman CN, Kooy
> HM, [Fine HA]{.underline}, Nedzi LA, Silver B, Riese NE, Black P McL.
> Results of stereotactic brachytherapy used in the initial management
> of patients with glioblastomas. J Nat Cancer Inst. 82(24): 1918-21,
> 1990.
>
> 4\. Loeffler JS, Macklis RM, Wen PY, [Fine HA]{.underline}, Alexander
> E III, Coleman CN. Alternative and future strategies in the treatment
> of malignant gliomas. Semin Rad Oncol. 1: 69-78, 1991.
>
> 5\. Loeffler JS, Alexander E III, Shea WM, Wen PY, [Fine
> HA,]{.underline} Kooy HM, Black PM. Radiosurgery as part of the
> initial management of patients with malignant gliomas. J Clin Oncol.
> 10(9): 1379-85, 1992.
>
> 6\. [Fine HA]{.underline}, Antman KH. High-dose chemotherapy with
> autologous bone marrow transplantation in the treatment of high grade
> astrocytomas in adults: therapeutic rationale and clinical experience.
> Bone Marrow Transplantation. 10(4): 315-21, 1992.
>
> 7\. [Fine HA]{.underline}, Dear KB, Loeffler JS, Black PM, Canellos
> GP. Meta-analysis of radiation therapy with and without adjuvant
> chemotherapy for malignant gliomas in adults. Cancer. 71(8): 2585-97,
> 1993.
>
> 8\. Manome Y, Datta R, [Fine HA]{.underline}. Early response genes
> induction following exposure to DNA damaging agents in
> astrocytoma-derived cell lines. Biochem Pharm. 45(8):1677-84, 1993.
>
> 9\. Levin JM, Schiff D, Loeffler JS, [Fine HA]{.underline}, Black PM,
> Wen PY. Complications of therapy for venous thromboembolic disease in
> patients with brain tumors. Neurology. 43(6): 1111-4, 1993.

10. [Fine HA]{.underline}, Mayer R. Primary central nervous system
    lymphoma. Ann Int Med. 119(11):1093-1104, 1993.

11\. Manome Y, Weichselbaum RR, Kufe DW, [Fine HA]{.underline}. Effect
of Bcl-2 on ionizing radiation and
1-B-D-arabinofuranosylcytosine-induced internucleosomal DNA
fragmentation and cell survival in human myeloid leukemia cells.
Oncology Res. 5(3): 139-44, 1993.

12\. Wen PY, Alexander E, Black PM, [Fine HA]{.underline}, Riese N,
Levin JM, Loeffler JS. Long term results of stereotactic brachytherapy
used in the initial treatment of patients with glioblastomas. Cancer
73(12): 3029-3036, 1994.

13\. [Fine HA]{.underline}. The basis for current treatment
recommendations for malignant gliomas. J Neuro-Onc. 20(2):111-120, 1994.

14\. [Fine HA]{.underline}. Prospects for gene therapy as an innovative
approach to malignant gliomas. Prospectives in Neurosurg. 5: 115-127,
1994.

15\. [Fine HA]{.underline}. Brain Tumor chemotherapy trials: slow start,
but quickly gaining. J Clin Oncol. 12:(10): 2003-4, 1994.

16\. Manome Y, Abe M, Hager MF, [Fine HA]{.underline}, Kufe DW. Enhancer
sequences of the DF3 gene regulate expression of the herpes simplex
virus thymidine kinase gene and confer sensitivity of human breast
cancer cells to gancoclovir. Cancer Res. 54(20): 5408-5413, 1994.

17\. Alexander E, Moriarty TM, Davis RB, Wen PY, [Fine HA]{.underline},
Black PM, Kooy HM, Loeffler JS. Stereotactic radiosurgery for the
definitive, noninvasive treatment of brain metastases. J. Natl Cancer
Inst. 87(1): 34-40, 1995.

18\. Shrieve DC, Alexander E III, Wen PY, [Fine HA]{.underline}, Kooy
HM, Black PM, Loeffler JS. Comparison of stereotactic radiosurgery and
brachytherapy in the treatment of recurrent glioblastoma multiforme.
Neurosurgery 36(2): 275-282, 1995.

19\. Loeffler JS, Shrieve DC, Wen PY, [Fine HA]{.underline}, Kooy HM,
Addesa AE, Black PM, Alexander E III. Radiosurgery for intracranial
malignancies. Sem Rad. Oncol. 5(3): 225-234, 1995.

20\. Wen PY, [Fine HA]{.underline}, Black PM, Shrieve DC, Alexander E
III, Loeffler JS. High-grade astrocytomas. Neurol Clin. 13(4): 875-900,
1995.

21\. [Fine HA]{.underline}. Novel biologic therapies of malignant
gliomas. Antiangiogenesis, immunotherapy, and gene therapy. Neurol Clin.
13(4): 827-46, 1995.

22\. [Fine HA]{.underline}. Treatment of Primary Central Nervous System
Lymphoma: Still More questions than answers. Blood. 86(8): 2873-2875,
1995.

23\. Chen L, Chen D, Manome Y, Dong Y, [Fine HA]{.underline}, Kufe, DW.
Breast cancer selective gene expression and therapy mediated by
recombinant adenoviruses containing the DF3/MUC1 promoter. J Clin
Invest. 96(6): 2775-2782, 1995.

24\. Manome Y, Wen PY, Hershowitz A, Tanaka T, Rollins BJ, Kufe DW,
[Fine HA.]{.underline} Monocyte Chemoattractant Protein-1 (MCP-1) Gene
transduction: an effective tumor vaccine strategy for non-intracranial
tumors. Cancer Immunol Immunother. 41(4): 227-235, 1995.

25\. Manome Y, Yao XJ, Kufe DW, Cohen EA, [Fine HA.]{.underline}
Selective effects of DNA damaging agents on HIV LTR activation and virus
replication in-vitro. J Acq Imm Def Synd and Hum Retrovir. 11(2):
109-116, 1996.

26\. Manome Y, Wen PY, Chen L, Tanaka T, Parr M, Dong Y,Yamazoe M,
Hirshowitz A, Kufe DW, [Fine HA]{.underline}. Gene therapy for malignant
gliomas using replication incompetent retroviral and adenoviral vectors
encoding the cytochrome P450 2B1 gene together with cyclophosphamide.
Gene Therapy. 3(6): 513-520, 1996.

27\. Dong Y, Wen P, Manome Y, Parr M, Hirshowitz A, Chen L, Hirschowitz
EA, Crystal R, Weichselbaum R, Kufe DW, [Fine HA]{.underline}. In vivo
replication-deficient adenovirus vector-mediated transduction of the
cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine.
Human Gene Therapy. 7(6): 713-720, 1996.

28\. Chen L, Pulsipher M, Chen D, Sieff C, Elias A, [Fine
HA]{.underline}, Kufe, DW. Selective transgene expression for detection
and elimination of contaminating carcinoma cells in hematopoietic stem
cell sources. J Clin Invest. 98: 2539-48, 1996.

29\. Manome Y, Wen PY, Dong Y, Tanaka T, Mitchell B.S., Kufe DW, [Fine
HA]{.underline}. Viral vector transduction of the human deoxycytidine
kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine
arabinoside in vitro and in vivo. Nature Medicine. 2(5): 567-573, 1996.

30\. [Fine HA]{.underline}, Wen, PY, Robertson M, O'Neil A, Kowal J,
Loeffler JS, Black PM. A phase I trial of a new recombinant human
interferon Beta (BG9015) for the treatment of patients with recurrent
gliomas. Clin Cancer Res. 3(3): 381-387, 1997.

31\. Tanaka T, Manome Y, Wen PY, Kufe DW, [Fine HA]{.underline}. Viral
vector-mediated transduction of a modified platelet factor 4 cDNA
inhibits angiogenesis and tumor growth. Nature Medicine. 3(4): 437-42,
1997.

32\. Parr MJ, Manome Y, Tanaka T, Wen P, Kufe D, Kaelin WG, [Fine
HA]{.underline}. Tumor-selective transgene expression in vivo mediated
by an E2F-responsive adenoviral vector. Nature Medicine. 3(10):
1145-1149, 1997.

33\. Parr MJ, Wen PY, Schaub M, Khoury SJ, Sayegh MH, [Fine
HA]{.underline}. Immune parameters affecting adenoviral vector gene
therapy in the brain. J Neurovirol. 4(2): 194-203, 1998.

34\. Tanaka, T, Cao Y, Folkman, J, [Fine HA.]{.underline} Viral
vector-targeted anti-angiogenic gene therapy utilizing an angiostatin
cDNA. Cancer Research. 58(15): 3362-3369, 1998.

35\. Maher E, [Fine HA]{.underline}. Primary central nervous system
lymphoma. Current state of our knowledge and future directions. Seminars
in Oncology. 26(3): 346-356, 1999.

36\. [Fine HA.]{.underline} Future directions in the management of
malignant gliomas. In: The Brain and The nervous System, [H.A.
Fine]{.underline} (ed.). Current Opinion on Oncology: 1-10, 1999.

37\. Newton NB, [Fine HA.]{.underline} NCCN clinical practice guidelines
for non-immunosuppressored primary CNS lymphoma. Oncology. 13: 153-160,
1999.

38\. Shrieve DC, Alexander E III, Black PM Wen PY, [Fine
HA]{.underline}, Kooy HM, Loeffler JS. Treatment of patients with
primary glioblastoma multforme with standard postoperative radiotherapy
and radiosurgical boost: prognostic factors and term outcome. J
Neurosurg. 90(1):72-7, 1999.

39\. [Fine HA]{.underline}, Figg WD, Jaeckle K, Wen PY, Kyritsis AP,
Loeffler JS, Levin VA, Black, PM, Kaplan R, Pluda JM, Yung WK. A phase
II trial of the anti-angiogenic agent, thalidomide, in patients with
recurrent high grade gliomas. J Clin Onc. 18(4): 708-715, 2000.

40\. Park CC, Hartmann C, Folkerth R, Loeffler JS, Wen PY, [Fine
HA]{.underline}, Black, PM, Shafman T, Louis DN. Systemic metastasis in
glioblastoma may represent the emergence of neoplastic subclones. J
Neuropath Exp Neurol. 59(12): 1044-1050, 2000.

41\. [Fine HA]{.underline}: Editors perspective of neuro-oncology over
the last two decades. In: Classic Papers in Neurologic Cancers, Journal
of Clinical Oncology, HA Fine ed., (In Press) 2000.

42\. [Fine, HA]{.underline}. Chemotherapy for brain tumors. J Nsu Quar,
(In Press) 2001.

43\. Inskip PD, Tarone RE, Hatch EE, Wilcosky TC, Shapiro WR, Selker RG,
[Fine HA]{.underline}, Black PM, Loeffler JS, Linet MS.
Cellular-telephone use and brain tumors. The New England Journal of
Medicine. 344 (2): 79-86, 2001.

44\. Inskip PD, Tarone RE, Hatch EE, Wilcosky TC, Shapiro WR, Selker RG,
[Fine HA,]{.underline} Black PM, Loeffler JS, Linet MS.
Cellular-telephone use and brain tumors. N Engl J Med. 344(2): 79-86,
2001.

45\. Hampl M, Tanaka T, Albert PS, Lee J, Ferrari N, [Fine
HA.]{.underline} Therapeutic effects of viral vector-mediated
antiangiogenic gene transfer in malignant ascites. Human Gene Therapy.
12:1713-1729, 2001.

46\. Lee J, Hampl M, Albert P, [Fine HA.]{.underline} Anti-tumor
activity and prolonged expression from a TRAIL-expressing adenoviral
vector. Neoplasia. 4: 312-323, 2002.

47\. Buetow KH, Klausner RD, [Fine HA]{.underline}, Kaplan R, Singer DS,
Strausberg RL. Cancer molecular analysis project: weaving a rich cancer
research tapestry. Cancer Cell. 1: 315-18, 2002.

48\. Brenner AV, Linet MS, [Fine HA]{.underline}, Shapiro WR, Selker RG,
Black PM, Inskip PD. History of allergies and autoimmune disease and
risk of brain tumors in adults. Int J Cancer. 99(2):252-9, 2002.

49\. Houghton PJ, Adamson PC, Blaney S, [Fine HA]{.underline}, Gorlick
R, Haber M, Helman, L, Hirschfeld S, Hollingshead MG, Israel MA, Lock
RB, Maris JM, Merlino G, Patterson W, Reynolds CP, Shannon K, Yu A,
Smith MA. Testing of new agents in childhood cancer preclinical models:
meeting summary. Clin Cancer Res. 8(12): 3646-3657, 2002**.**

50\. Kunschner LJ, [Fine H]{.underline}, Hess K, Jaeckle K, Kyritsis AP,
Yung WK.CI-980 for the treatment of recurrent or progressive malignant
gliomas: national central nervous system consortium phase I-II
evaluation of CI-980. Cancer Invest. 20: 948-54, 2002.

51\. [Fine HA]{.underline}. Primary central nervous system lymphoma:
time to ask the question. J Clin Oncol. 20(24): 4615-7, 2002.

52\. [Fine HA]{.underline}. Polyomavirus and Medulloblastoma: a smoking
gun or guilt by association? JNCI. 94(4): 240-1, 2002.

53\. Inskip PD, Tarone RE, Hatch EE, Wilcosky TC, Selker RG, [Fine
HA]{.underline}, Black PM, Loeffler JS, Shapiro WR, Linet MS. Laterality
of brain tumors. Neuroepidemiology, 22(2): 130-8, 2003.

54\. De Roos AJ, Rothman N, Inskip PD, Linet MS, Shapiro WR, Selker RG,
Fine HA, Black PM, Pittman GS, Bell DA. Genetic polymorphisms in GSTM1,
-P1, -T1, and CYP2E1 and risk of adult brain tumors. Cancer
Epidemiology, Biomarkers and Prevention. 12(1): 14-22, 2003.

55\. Brenner AV, Linet MS, Selker RG, Shapiro WR, Black PM, [Fine
HA]{.underline}, Inskip PD.

Polio vaccination and risk of brain tumors in adults: no apparent
association. Cancer Epidemiol Biomarkers Prev. 12(2): 177-8, 2003.

56\. Inskip PD, Tarone RE, Brenner AV, [Fine HA]{.underline}, Black PM,
Shapiro WR, Selker RG, Linet MS. Handedness and risk of brain tumors in
adults. Cancer Epidemiol Biomarkers Prev. 12(3): 223-5, 2003.

57\. Prados MD, Schold SC JR SC, [Fine HA]{.underline}, Jaeckle K,
Hochberg F, Mechtler L, Fetell MR, Phuphanich S, Feun L, Janus TJ, Ford
K, Graney W. A randomized, double-blind, placebo-controlled, phase 2
study of RMP-7 in combination with carboplatin administered
intravenously for the treatment of recurrent malignant glioma.
Neuro-oncology. 5(2): 96-103, 2003.

58\. Jaeckle1 KA, Hess KR, Alfred Yung WKA, Greenberg, H, [Fine
H]{.underline}, Schiff D, Pollack IE, Kuhn J, Fink K, Mehta M, Cloughesy
T, Nicholas K, Chang S, Prados M. A phase II evaluation of temozolomide
(SCH52365) and 13-Cis- Retinoic Acid (Isotretinoin; cRA) for the
treatment of recurrent and progressive malignant alioma: A North
American Brain Tumor Consortium (NABTC) Study. J. Clin Oncol. 21:
2305-11, 2003.

59\. Ferrari N, Glod J, Lee J, Kobiler D, [Fine HA]{.underline}. Bone
marrow-derived, endothelial progenitor-like cells as
angiogenesis--selective gene targeting vectors. Gene Therapy 10(8):
647-56, 2003.

60\. De Roos AJ, Stewart PA, Linet MS, Heineman EF, Dosemeci M, Wilcosky
T, Shapiro WR, Selkar RG, [Fine HA]{.underline}, Black PM, Inskip PD.
Occupation and the risk of adult glioma in the United States. Cancer
Causes and Control. 14(2):139-150, 2003.

61\. [Fine HA]{.underline}, Wen PY, Maher EA, Viscosi E, Batchelor T,
Lakhani N, Figg WD, Purow BW, Borkowf CB. A phase II trial of
Thalidomide and BCNU for patients with recurrent high grade gliomas. J.
Clin Oncol. 21(12): 2299-304, 2003.

62\. Inskip PD, Tarone RE, Hatch EE, Wilcosky TC, [Fine HA]{.underline},
Black PM, Loeffler JS, Shapiro WR, Selker RG, Linet MS. Sociodemographic
indicators and risk of brain tumours. Int J Epidemiol. 32(2): 225-33,
2003.

63\. Lee J, Elkahloun AG, Messina SA, Ferrari N, Xi D, Smith CL, Cooper
R Jr, Albert PS, [Fine HA]{.underline}. Cellular and genetic
characterization of human adult bone-marrow-derived neural stem-like
cells: a potential anti-glioma cellular vector. Cancer Res. 63(24):
8877-89, 2003.

64\. Hill DA, Inskip PD, Shapiro WR, Selker RG, [Fine HA]{.underline},
Black PM, Linet MS. Cancer in first-degree relatives and risk of glioma
in adults. Cancer Epidemiol Biomarkers Prev. 12(12):1443-8, 2003.

65\. Prados MD, Yung WK, Jaeckle KA, Robins HI, Mehta MP, [Fine
HA]{.underline}, Wen PY, Cloughesy TF, Chang SM, Nicholas MK, Schiff D,
Greenberg HS, Junck L, Fink KL, Hess KR, Kuhn J. Phase I trial of
irinotecan (CPT-11) in patients with recurrent malignant glioma. A North
American Brain Tumor Consortium study. Neuro-Oncol. 6(1): 44-54, 2004.

66\. Prados MD, Yung WKA, [Fine HA,]{.underline} Greenberg HS, Junck L,
Chang SM, Nicholas MK, Robins HI, Mehta MP, Fink KL, Jaeckle KA, Kuhn J,
Hess KR, Schold SC. A Phase II study of BCNU and Temozolomide for
recurrent glioblastoma multiforme: A North American Brain Tumor
Consortium Study. Neuro-Oncology. 6(1): 33-7, 2004.

67\. Tohnya, TM, Kim, S, [Fine HA,]{.underline} Dunn, L. Figg, WD,
Sparreboom, A. Determination of SU5416, a novel angiogenesis inhibitor
in human plasma by liquid chromatography. J of Chromatography B. 805(1):
135-40, 2004.

68\. Purow B, [Fine HA]{.underline}. Progress Report on the potential of
angiogenesis inhibitors for neuro-oncology. Cancer Investigation. 22(4):
577-587, 2004.

69\. [Fine HA]{.underline}. Toward a Glioblastoma Vaccine: Promise and
potential pitfalls. J Clin. Oncol. 22(21): 4240-3, 2004.

70\. [Fine HA]{.underline}, Loeffler JS. Large Cell: Primary CNS. In The
Lymphomas. Canellos G, Lister AT, Young B, 2^nd^ Edition, Elsevier
Press: 309-324, 2004.

71\. Purow BJ, [Fine HA]{.underline}. Anti-angiogenic therapy for
primary and metastatic brain tumors. Hematology/Oncology Clinics of
North America, 18(5): 1161-81, 2004.

72\. Rajaraman P, De Roos AJ, Stewart PA, Linet MS, [Fine
HA]{.underline}, Shapiro WR, Selker RG, Black PM Inskip PD. Occupation
and risk of meningioma and acoustic neuroma in the United States. Am J
Ind Med. 45(5): 395-407, 2004.

73\. Chang SM, Prados MD, Yung WK, [Fine H]{.underline}, Junck L,
Greenberg H, Robins HI, Mehta M, Fink KL, Jaeckle KA, Kuhn J, Hess K,
Schold C. Phase II study of neoadjuvant 1, 3-bis
(2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed
anaplastic glioma: a North American Brain Tumor Consortium Trial.
Cancer. 100(8): 1712-6, 2004.

74\. Brenner AV, Linet MS, Shapiro WR, Selker RG, [Fine HA]{.underline},
Black PM, Inskip PD. Season of birth and risk of brain tumors in adults.
Neurology. 63(2): 276-81, 2004.

75\. Hui AM, Zhang W, Chen W, Xi D, Purow B, Friedman GC, [Fine
HA]{.underline}. Agents with selective estrogen receptor modulator
activity induce apoptosis in vitro and in vivo in estrogen
receptor-negative glioma cells. Cancer Research. 64: 9115-9123, 2004.

76\. Tohnya TM, Hwang K, Lepper ER, Fine HA, Dahut WL, Venitz J,
Sparreboom A, Figg WD. Determination of CC-5013, an analogue of
thalidomide, in human plasma by liquid chromatography---mass
spectrometry. J Chromatography B. 811: 135-141, 2004.

77\. Hill DA, Linet MS, Black PM, [Fine HA]{.underline}, Selker RG,
Shapiro WR, Inskip PD. Meningioma and schwannoma risk in adults in
relation to family history of cancer. Neuro-oncol. 6(4): 274-80, 2004.

78\. Chen W, Lee J, Cho S. [Fine HA]{.underline}. Proteosome-mediated
destruction of the cyclin A/cyclin-dependent kinase 2 complex suppresses
tumor cell growth in vitro and in vivo. Cancer Research. 64(11):
3949-57, 2004.

79\. Sun L, Lee J, [Fine HA]{.underline}. Neuronally expressed stem cell
factor induces neural stem cell migration to areas of brain injury. J
Clin Invest. 113(9): 1364-1374, 2004.

80\. [Brem SS, Bierman PJ, Black P, Blumenthal DT, Brem H, Chamberlain
MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, [Fine HA]{.underline},
Friedman A, Glass J, Grossman SA, Heimberger AB, Junck L, Levin V,
Loeffler JJ, Maor MH, Narayana A, Newton HB, Olivi A, Portnow J, Prados
M, Raizer JJ, Rosenfeld SS, Shrieve DC, Sills AK Jr, Spence AM, Vrionis
FD; National Comprehensive Cancer
Network.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16194456&query_hl=1&itool=pubmed_docsum)Central
nervous system cancers: Clinical Practice Guidelines in Oncology. J Natl
Compr Canc Netw. 3(5): 644-90, 2005.

81\. [Rajaraman P, Schwartz BS, Rothman N, Yeager M, [Fine
HA]{.underline}, Shapiro WR, Selker RG, Black PM, Inskip
PD.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16140629&query_hl=1&itool=pubmed_docsum)
Delta-aminolevulinic acid dehydratase polymorphism and risk of brain
tumors in adults.Environ Health Perspect. 113: 1209-11, 2005.

82\. Kleinerman RA, Linet MS, Hatch EE, Tarone RE, Black PM, Selker RG,
Shapiro WR, [Fine HA]{.underline}, Inskip PD. Self-reported electrical
appliance use and risk of adult brain tumors.\
Am J Epidemiol. 161(2): 136-46, 2005.

83\. Camphausen K, Cerna D, Scott T, Sproull M, Burgan WE, Cerra MA,
[Fine HA]{.underline}, Tofilon PJ. Enhancement of in vitro and in vivo
tumor cell radiosensitivity by valproic acid. Int J Cancer 114(3):
380-6, 2005.

84\. Hatch EE, Linet MS, Zhang J, [Fine HA]{.underline}, Shapiro WR,
Selker RG, Black PM, Inskip PD. Reproductive and hormonal factors and
risk of brain tumors in adult females. Int J Cancer. 1;114(5): 797-805,
2005.

85\. [Cho SY, Ravasi L, Szajek LP, Seidel J, Green MV, [Fine
HA]{.underline}, Eckelman
WC.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16269608&query_hl=1&itool=pubmed_docsum)
Evaluation of (76)Br-FBAU as a PET reporter probe for HSV1-tk gene
expression imaging using mouse models of human glioma. J Nucl Med. 46:
1923-30, 2005.

86\. Anderson SA, Glod J, Arbab As, Noel N. Asharia P, [Fine
HA]{.underline}, Frank JA. Non-invasive MR imaging of magnetically
labeled stem cells to directly identify neovasculature in a glioma
model. Blood. 105: 420-5, 2005.

87\. Purow BW, Haque RM, Noel MW, Su Q, Burdick MJ, Lee J, Sundaresan T,
Pastorino S, Park JK, Mikolaenko I, Maric D, Eberhart CG, [Fine
HA]{.underline}. Expression of Notch-1 and its ligands, Delta-like-1 and
Jagged-1, is critical for glioma cell survival and proliferation. Cancer
Research. 65(6): 2353-63, 2005.

88\. [Fine HA.]{.underline} Radiotherapy plus adjuvant temozolomide for
the treatment of glioblastoma---a paradigm shift. Nat Clin Pract Oncol.
2: 334-5, 2005.

89\. De Roos, AJ, Rothman N, Brown M, Bell DA, Pittman GS, Shapiro WR,
Selker RG, [Fine HA]{.underline}, Black PM, Inskip PD. Variation in
genes to aromatic hydrocarbon metabolism and the risk of adult brain
tumors. Neuro-Oncology. 8(2): 145-55, 2006.

90\. Glod J, Kobiler D, Noel M, Koneru R, Lehrer S, Messina D, Shoshona
L, Messina D, Dragen M, [Fine HA]{.underline}. Monocytes form a vascular
barrier and participate in vessel repair after brain injury. Blood.
107:940-46, 2006 .

91\. Sun L, Hui A-M, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S,
Passanti A, Menon J, Bailey R, Rolsenblum M, Mikkelson T, [Fine
HA]{.underline}. Neuronal and Glioma-Derived Stem Cell Factor Induces
Angiogenesis within the Brain. Cancer Cell. 9: 287-300, 2006.

92\. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino
S, Purow BW, Christopher N, Zhang W Park JK, [Fine. HA.]{.underline}
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF
more closely mirror the phenotype and genotype of primary tumors than do
serum cultured cell lines. Cancer Cell. 9(5): 391-403, 2006.

93\. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE,
Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D,
Lieberman F, [Fine HA]{.underline}, Mehta M, Robins HI, DeAngelis LM,
Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, Aldape K, Hayes M,
Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgo AJ, Stiles C, Prados
MD. Phase I/II study of Imatinib Mesylate (Gleevec) for recurrent
malignant gliomas: North American Brain Tumor Consortium Study 99-08.
Clin Cancer Res.15:12(16): 4899-907, 2006.

94\. Kotliarov Y, Steed ME, Christopher N, Walling J, Su Q, Center A,
Heiss J, Rosenblum M, Mikkelsen T, Zenklusen JC and [Fine
HA]{.underline}. High-Resolution Global Genomic Survey of 178 Gliomas
Reveals Novel Regions of Copy Number Alteration and Allelic Imbalances.
Cancer Research. 66(19): 9428-36, 2006.

95\. Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, [Fine
HA]{.underline}, Wen PY, Cloughesy T, Chang Nicholas MK, Schiff D,
Greenberg H, Junck L, Fink K, Hess K, Kuhn J. A phase 2 trial of
iriotecan (CPT-11) in patients with recurrent malignant glioma: a North
American Brain Tumor Consortium study. Neuro-Oncology.8: 189-93, 2006.

96. Lamborn K, Yung WK, Chang S, Wen PY, Cloughesy TF, DeAngelis LM,
    Robins HI, Lieberman F, [Fine HA]{.underline}, Fink KL, Junck L,
    Abrey L, Gilbert MR, Mehta M, Kuhn J, Aldape K, Hibberts J, Peterson
    P, Prados MD. Progression-free survival- a clinically meaningful
    endpoint for evaluating therapy for patients with recurrent
    high-grade gliomas. Neuro-Oncology, (In Press) 2006.

97\. Jiang W, Cazacu S, Xiang C, Zenklusen JC, [Fine HA]{.underline},
Berens ME, Rennert J, Brodie C, Mikkelsen T. Oncogenic Functions of
1GFBD-7 in Glioma Tumors. Cancer Research, (In Press) 2006.

98\. Ngo TT, Peng T, Liang XJ, Akeju O, Pastorino S, Zhang W, Kotliarov
Y, [Fine]{.underline}

> [HA]{.underline}, Maric D, Wen P, De Girolami U, Black P, Wu W, Shen
> RF, Kang DW, Park J. The 1p encoded protein stathmin modulates the
> resistance of malignant gliomas to nitrosoureas. Journal of the
> National Cancer Institute, 2007 Apr 18;99(8):639-52.

99. Rajaraman P, Wang SS, Rothman N, Brown MM, Black PM, [Fine
    HA]{.underline}, Loeffler JS, Selker RG, Shapiro WR, Chanock SJ,
    Inskip PD. Polymorphisms in Apoptosis and Cell-Cycle Control Genes
    and Risk of Brain Tumors in Adults. Cancer Research, 2007
    Aug;16(8):1655-61.

100. Rajaraman P, Stewart PA, Samet JM, Schwartz BS, Linet MS, Zahm SH,

> Rothman N, Yeager M, [Fine HA]{.underline}, Black PM, Loeffler J,
> Shapiro WR, Selker RG, Inskip PD. Lead, genetic susceptibility, and
> risk of adult brain tumors. Cancer Epidemiol Biomarkers. 15(12):
> 2514-20, 2006.

101. Bluhm EC, Zahm SH, [Fine HA]{.underline}, Black PM, Loeffler JS,
     Shapiro WR, Selker RG, Inskip PD. Personal hair dye use and risk of
     glioma, meningioma, and acoustic neuroma among adults. American
     Journal of Epidemiology. 165(1): 63-71, 2007.

102. Brenner AV, Butler MA, Wang SS, Ruder AM, Rothman N, Schulte PA,
     Chanock SJ, Fine HA, Linet MS, Inskip PD. Single-nucleotide
     polymorphisms in selected cytokine genes and risk of adult glioma.
     Carcinogenesis. 2007 Dec;28(12):2543-7.

103. Fine, HA. Promising new therapies for malignant gliomas. Cancer J.
     2007 Nov-Dec;13(6):349-54.

104\. Fine HA, Kim L, Albert PS, Duic JP, Ma H, Zhang W, Tohnya T, Figg
WD, Royce C. A phase I trial of lenalidomide in patients with recurrent
primary central nervous system tumors.Clin Cancer Res. 2007 Dec
1;13(23):7101-6.

105\. [Lee J, Son MJ, Woolard K, Donin NM, Li A, Cheng CH, Kotliarova S,
Kotliarov Y, Walling J, Ahn S, Kim M, Totonchy M, Cusack T, Ene C, Ma H,
Su Q, Zenklusen JC, Zhang W, Maric D, Fine
HA.](http://www.ncbi.nlm.nih.gov/pubmed/18167341?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum)
Epigenetic-mediated dysfunction of the bone morphogenetic protein
pathway inhibits differentiation of glioblastoma-initiating cells.
Cancer Cell. 2008 Jan;13(1):69-80.

106. Li A, Walling J, Kotliarov Y, Center A, Steed ME, Ahn SJ, Rosenblum
     M, Mikkelsen T, Zenklusen JC, Fine HA. Genomic changes and gene
     expression profiles reveal that established glioma cell lines are
     poorly representative of primary human gliomas. Mol Cancer Res.
     2008 Jan;6(1):21-30.

107. Notch-1 Regulates Transcription of the Epidermal Growth Factor
     Receptor Through p53. (In Press)

108. FK506 Binding Protein Mediates Glioma Cell Growth and Sensitivity
     to Rapamycin Treatment by Regulating NK-kB Singaling Pathway.
     Jiang, W, Cazacu, S, Xiang, C, Zenklusen, J, Fine, HA, Berens, M,
     Armstrong, B, Brodie, C, Mikkelsen, T. NeoPlasia 10:3, March 2008
     235-243.

[Book Chapters]{.underline}

1\. [Fine HA]{.underline}, Loeffler JS. Primary Central Nervous System
Lymphoma. In: Canellos GP, Lister TA, Sklar JL, eds. The Lymphomas.
Philadelphia, W.B. Saunders Co., 1988: 481-94.

> 2\. Loeffler JS, Alexander E III, Kooy HM, Wen PY, [Fine
> HA,]{.underline} Black P McL. Radiosurgery for Brain Metastasis. In:
> DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and
> Practice of Oncology, Update. Philadelphia: JB Lippincott, 1991:1-13.
>
> 3\. Loeffler JS, Alexander E III, Wen PY, [Fine HA]{.underline}, Kooy
> HM, Black PM. Radiosurgery for Colonic Brain Metastasis: 5 year
> experience at the Brigham and Women's Hospital. In: Landsford LD, ed.
> Radiosurgery Update. New York: Elsevier, 1992: 383-92.
>
> 4\. [Fine HA.]{.underline} Chemotherapy in the Treatment of Malignant
> Astrocytomas in Adults. In: Black P McL, Lampson L, eds. Astrocytomas.
> Boston: Blackwell, 1993: 86-110.
>
> 5\. [Fine HA,]{.underline} Haseltine WA. RNA Tumor Viruses. In:
> Holland JF, Frei E III, eds. Cancer Medicine, 3rd ed. Philadelphia:
> Lea and Febiger, 1993: 265-82.
>
> 6\. Alexander E III, Black P McL, Wen PY, [Fine H]{.underline},
> Loeffler JS. Results of radiosurgery versus brachytherapy for
> malignant gliomas. In: DeSalles AAF, Goetsch SJ, eds. Stereotactic
> Surgery and Radiosurgery. Madison: Medical Physics Publishing, 1993:
> 455-61.
>
> 7\. Antman KH, Elias A, [Fine HA.]{.underline} Dose Intensive Therapy
> in Solid Tumors. In: Forman SJ, Blume C, Thomas ED, eds. Bone Marrow
> Transplantation. Blackwell Scientific Publications. Cambridge.
> Blackwell Scientific Publications, 1993: 767-789.
>
> 8\. [Fine HA]{.underline}, Pluard T. Tumor Angiogenesis: Biology and
> Therapeutic Implications. In: Mauch P, Loeffler J, eds. Radiation
> Oncology: Technology and Biology. Philadelphia: W.B. Saunders Co.,
> 1994: 487-509.
>
> 9\. [Fine HA]{.underline}. Primary Tumors of the Central Nervous
> System. In: Macdonald JS, Haller D, Mayer R. eds. Manual of Oncologic
> Therapeutics (3rd edition), Philadelphia, J.B. Lippincott, 1995:
> 261-271.

10\. [Fine HA]{.underline}, Kufe DW. Gene Therapy. In: Holland JF, Frei
E III, eds. Cancer Medicine, 3rd ed. Philadelphia: Lea and Febiger, (In
Press) 1995

11\. [Fine HA]{.underline}. Novel Biological-Based Therapies for
Malignant Gliomas. In Loeffler JS, Black PM, Fine HA, Wen PY. Cancers of
the Central Nervous System. Cambridge: Blackwell Scientific
Publications, 1997: 213-226.

12\. Rollins, BJ, [Fine HA]{.underline}, Gu L, Soejema K, Tsang S. Tumor
Infiltrating Monocytes and the Anti-Tumor Effects of Monocyte
Chemoattractant Protein-1. In: Cytokines, B.J. Rollins (ed), Humana
Press, Totowa, NJ, 1999.

13\. Warren KE, [Fine HA.]{.underline} Systemic Chemotherapy of Central
Nervous System Tumors. In: Brain Cancer M. Prados (ed), B.C. Decker
Inc., Hamilton, Ontario, Canada, 2002.

14\. Warren KE, [Fine HA]{.underline}. Principles of Chemotherapy. In:
Youman\'s Neurological Surgery-5^th^ edition, H. R. Winn (ed), W.B.
Saunders, Philadelphia, PA, 2003.

15\. [Fine, HA]{.underline}. CNS Malignancy and Clinical Pharmacology.
In: Pharmacokinetics and Pharmacodynamics of Anti-Cancer Drugs as part
of the Cancer Drug Discovery Series. Totowa, NJ, Humana Press, 2004:
373-393.

16\. [Fine HA]{.underline}, Loeffler JS, Markert J. Neoplasms of the
Central Nervous System. In: Cancer: Principles and Practice in Oncology.
V. DeVita, S. Rosenberg, S Helman (ed), 7^th^ Edition, (In Press) 2004.

17\. Glod J, [Fine HA]{.underline}. Endothelial Progenitor Cells,
Vasculogenesis, and Their Contribution to New Blood Vessel Formation in
the Adult. In: Encyclopedia of the Microvasculature, Elsevier Press,
2004: 105-109.

18\. [Fine HA]{.underline}, Kim L. Central Nervous System Tumors. In:
Oncology-Hematology Source Book. M.Boyiadzis, J. Frame, P. Lebowitz, and
T. Fojo (eds), McGraw Hill, (In Press) 2004.

19\. [Fine HA]{.underline}, Loeffler JS. Large Cell: Primary CNS. In:
The Lymphomas. G Canellos, T. Andrew Lister, and Brian Young (eds),
2^nd^ Edition, Elsevier Press, (In Press) 2004.

20. Mansky P, Duic P, [Fine HA]{.underline}. Central Nervous System
    Tumors. In: Bethesda Handbook of Clinical Oncology. J. Abraham, C.J.
    Allegra, and James Gulley (eds), 2^nd^ Edition, Lippincott Williams
    & Wilkins, 2004: 433-453.

21. [Fine HA]{.underline}, Kim L. Central Nervous System Tumors. In:
    Oncology-Hematology source book. Boyiadzis M, Frame J, Lebowitz P,
    Fojo T, McGraw Hill, 2004: 26-27.

22. Glod J, [Fine HA]{.underline}. Endothelial Progenitor Cells,
    Vasculogenesis, and their contribution to new blood vessel formation
    in the adult. In: Encyclopedia of the Microvasculature, Elsevier,
    2004: 105-109.

23. [Fine HA]{.underline}, Barker FG, Markert J, Loeffler JS. Neoplasms
    of the Central Nervous System. In: Cancer: Principles and practice
    in Oncology. V. DeVita, S. Rosenberg, S Helman (ed), 7^th^ Edition,
    2005: 1834-1887.

24. Zhang W, [Fine HA]{.underline}. Mechanisms of Gliomagenesis: Cell
    Cycle in the Central Nervous System. D Janigro, Humana Press, 2006:
    449-462.

25. Elinzano H, [Fine HA]{.underline}. Antiangiogenic Therapy for
    Gliomas. Promise and Pitfalls. In: Antiangiogenic Cancer Therapy"
    CRC Press, (In Press*)* 2006*.*

26. Warren K, [Fine, HA]{.underline}. Antiangiogenic Therapy for Brain
    Tumors. In: Antiangiogenic Agents in Cancer Therapy-2^nd^ edition,
    BA.Teicher, LM.Ellis ed. Humana Press, (In Press) 2006.

[Editorials]{.underline}

> 1\. [Fine HA]{.underline}. Chemotherapy Trials in Brain Tumors: Slow
> Start, But Quickly Gaining. J Clin Oncol. 12: (10): 2003-2004, 1994.
>
> 2\. [Fine HA.]{.underline} Treatment of Primary Central Nervous System
> Lymphoma: Still More Questions than Answers. Blood 86:2873-5, 1995.
>
> 3\. [Fine HA.]{.underline} Polyomavirus and Medulloblastoma: A Smoking
> Gun or Guilt By Association? JNCI, Volume 94, No. 4, 2002.

4.  [Fine HA.]{.underline} Primary Central Nervous System Lymphoma: Its
    Time We Ask a Question. J

> Clin. Oncol. 20:4615-7, 2002.

5.  [Fine HA]{.underline}. Toward a Glioblastoma Vaccine: Promise and
    Potential Pitfalls. J Clin. Oncol. 22(21):4240-3, 2004.

> 6\. [Fine HA]{.underline}. Radiotherapy plus adjuvant temozolomide for
> the treatment of glioblastoma---a paradigm shift**.** Nature Clinical
> Practice Oncology. 2:334-5, 2005